Quantification of Glecaprevir and Pibrentasvir with Deuterated Internal Standards in Spiked Human Plasma Samples by LC–ESI-MS/MS
Main Article Content
A fixed oral dose combination of Glecaprevir and Pibrentasvir used for the treatment of patients with viral infections
especially used as an NS5A inhibitor. Quantification of such drugs in human plasma somewhat help full. In this manuscript,
the authors developed a simple, sensitive, and specific liquid chromatography – tandem mass spectrometry method was
used for quantification of Glecaprevir and Pibrentasvir in human plasma using Glecaprevir-13C-d7 as internal standard.
Agilent TC-C18, 4.6 × 75 mm, 3.5 μm, 80 Å column, 5 mM ammonium acetate: Acetonitrile (20: 80 v/v) mobile phase
was used for chromatographic separation. MRM-positive mode was used to detect the Glecaprevir, Pibrentasvir, and
Glecaprevir-13C-d7 at m/z 838.87/337.26, 557.51/210.40, and 846.91/337.26, respectively. Liquid-liquid extraction
was employed in the extraction of analytes and internal standard from human plasma. This method is validated over a
linear concentration range of 50.0–10,000.0 pg/mL for Glecaprevir and Pibrentasvir with a correlation coefficient (r) of
≥0.9997. Both drugs were stable in plasma samples. The validated method was successfully.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.